Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P4GU | ISIN: US14147L1089 | Ticker-Symbol: XE7C
Tradegate
28.03.24
20:07 Uhr
4,870 Euro
-0,060
-1,22 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CARDIFF ONCOLOGY INC Chart 1 Jahr
5-Tage-Chart
CARDIFF ONCOLOGY INC 5-Tage-Chart
RealtimeGeldBriefZeit
4,8305,11028.03.
4,7755,08028.03.

Aktuelle News zur CARDIFF ONCOLOGY Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiCardiff Oncology, Inc. - S-8, Securities to be offered to employees in employee benefit plans4
21.03.Cardiff (CRDF) Stock Rallies 194% in a Month: Here's Why23
11.03.ETRN, CRDF and KC are among pre market gainers16
06.03.Cardiff Oncology, Inc.: Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024176SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...
► Artikel lesen
01.03.Earnings call: Cardiff Oncology reports promising trial results, extends cash runway17
01.03.Small Cap-Cardiff Oncology Outlines Data From Discontinued Colorectal Cancer Trial, Stock Soars11
01.03.Cardiff Oncology, DermTech, Precision Biosciences among healthcare movers7
01.03.Cardiff Oncology Inc reports results for the quarter ended in December - Earnings Summary21
29.02.Cardiff Oncology, Inc.: Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC310- New clinical data from second-line randomized ONSEMBLE trial provides further evidence of the efficacy of onvansertib in combination with FOLFIRI/bev in bev naïve RAS-mutated mCRC patients - - Company...
► Artikel lesen
29.02.Cardiff Oncology, Inc.: Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update157- First patient dosed in Phase 2 first-line trial in patients with RAS-mutated mCRC for new lead program with the support of FDA and clinical execution from Pfizer Ignite - - Interim topline data...
► Artikel lesen
29.02.Cardiff Oncology, Inc. - 8-K, Current Report2
29.02.Cardiff Oncology, Inc. - 10-K, Annual Report2
28.02.Cardiff Oncology Earnings Preview5
17.01.Cardiff Oncology, Inc.: Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research235- Findings from the Phase 1b portion of company's Phase 1b /2 study in second-line KRAS-mutated mCRC highlight the safety and promising efficacy of onvansertib in combination with standard-of-care...
► Artikel lesen
08.01.Cardiff Oncology, Inc. - 8-K, Current Report4
02.11.23Cardiff Oncology GAAP EPS of -$0.22 beats by $0.06, revenue of $0.14M beats by $0.1M12
02.11.23Cardiff Oncology, Inc. - 8-K, Current Report6
02.11.23Cardiff Oncology, Inc.: Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update703- Advance to first-line RAS-mutated metastatic colorectal cancer (mCRC) for lead program based on positive clinical and preclinical data and guidance from FDA - - Expanded relationship with Pfizer...
► Artikel lesen
02.11.23Cardiff Oncology, Inc. - 10-Q, Quarterly Report3
01.11.23Earnings Preview: Cardiff Oncology2
Seite:  Weiter >>
23 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1